Successful Drug Discovery 2018
DOI: 10.1002/9783527808694.ch9
|View full text |Cite
|
Sign up to set email alerts
|

Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti‐CD20 Antibody for the Treatment of Non‐Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 95 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?